Immune-related adverse events (AEs) are becoming more frequent in oncology patients receiving immunotherapy. To better understand emerging trends and education needs, the Association of Cancer Care Centers (ACCC) developed the Immuno-Oncology Census as part of its ongoing commitment to sharing up-to-date strategies for managing adverse events. In this episode, CANCER BUZZ speaks with Bat-ami Gordon, clinical research PhD candidate at the Icahn School of Medicine at Mount Sinai, who discusses best practices for cancer care providers to identify immune-related AEs caused by immunotherapy.

"Understanding the best practices for identification is going to be the best way we can start to implement better treatments for these immune-related adverse events." – Bat-ami Gordon

Bat-ami Gordon

Clinical Research PhD Candidate

Icahn School of Medicine Mount Sinai

New York, NY

Additional Reading/Sources

Icahn School of Medicine at Mount Sinai

ACCC Immune-Related Adverse Events Resources

Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors

ACCC Immuno-Oncology Census